These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9413543)

  • 1. Strategies to avoid virus transmissions by biopharmaceutic products.
    Werz W; Hoffmann H; Haberer K; Walter JK
    Arch Virol Suppl; 1997; 13():245-56. PubMed ID: 9413543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC; Miller JL; Petteway SR
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the clearance factor for transmissible spongiform encephalopathy agents during the manufacturing process of polygeline.
    Peano S; Reiner G; Carbonatto M; Bodenbender L; Boland P; Abel KJ
    Intensive Care Med; 2000 May; 26(5):608-12. PubMed ID: 10923737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of bovine spongiform encephalopathy.
    Kimberlin RH
    Dev Biol Stand; 1991; 75():75-82. PubMed ID: 1838995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
    [No Abstract]   [Full Text] [Related]  

  • 9. Gelatine production, the six steps to maximum safety.
    Schrieber R; Seybold U
    Dev Biol Stand; 1993; 80():195-8. PubMed ID: 8270109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
    Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
    [No Abstract]   [Full Text] [Related]  

  • 11. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing.
    Jiang M; Severson KA; Love JC; Madden H; Swann P; Zang L; Braatz RD
    Biotechnol Bioeng; 2017 Nov; 114(11):2445-2456. PubMed ID: 28710854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adventitious agents from animal-derived raw materials--a method of risk assessment.
    Foster LG
    Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of the biological safety of a drug derived from mammalian organs.
    Hübner GE; Koch RC; Sprenger KB; Stadler PJ; Gölker CF
    Arzneimittelforschung; 1996 Jun; 46(6):657-61. PubMed ID: 8767361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meeting Report: 2013 PDA Virus & TSE Safety Forum.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2014; 68(3):193-214. PubMed ID: 25188343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Heparin Purification Process Removes Spiked Transmissible Spongiform Encephalopathy Agent.
    Bett C; Grgac K; Long D; Karfunkle M; Keire DA; Asher DM; Gregori L
    AAPS J; 2017 May; 19(3):765-771. PubMed ID: 28116677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BSE--a risk for man through pharmaceutical products? Position and politics of the German pharmaceutical industry.
    Danner K
    Dev Biol Stand; 1993; 80():199-205. PubMed ID: 8270110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The research programme on transmissible spongiform encephalopathies in Britain with special reference to bovine spongiform encephalopathy.
    Bradley R
    Dev Biol Stand; 1993; 80():157-70. PubMed ID: 8270105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
    Lubiniecki AS; McAllister PR; Smith TM; Shadle PJ
    Dev Biol Stand; 1996; 88():309-15. PubMed ID: 9119154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.